Recombinant lipoprotein-based vaccine candidates against C. difficile infections

Journal of Biomedical Science

Volumn 22, Issue 1, 2015, Pages

  Huang, Jui Hsin ^a,b   Wu, Chia Wei ^a   Lien, Shu Pei ^a   Leng, Chih Hsiang ^a   Hsiao, Kuang Nan ^a   Liu, Shih Jen ^a   Chen, Hsin Wei ^a   Siu, Leung Kei ^a   Chong, Pele ^a,b,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adjuvant; Antibiotic associated pseudo membranous colitis; C. difficile toxins; Lipoprotein; Receptor binding domain; Toll like receptor agonist

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN A RECEPTOR BINDING DOMAIN; CLOSTRIDIUM DIFFICILE TOXIN B RECEPTOR BINDING DOMAIN; IMMUNOLOGICAL ADJUVANT; OVALBUMIN; RECOMBINANT LIPOPROTEIN CLOSTRIDIUM DIFFICILE TOXIN A RECEPTOR BINDING DOMAIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG; BACTERIAL TOXIN; BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE LETHAL TOXIN B; ENTEROTOXIN; HYBRID PROTEIN; LIPOPROTEIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL MATURATION; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DENDRITIC CELL; HAMSTER; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; VERO CELL LINE; ANIMAL; BAGG ALBINO MOUSE; CHLOROCEBUS AETHIOPS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GENETICS; IMMUNOLOGY; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE;

CLOSTRIDIUM DIFFICILE; CRICETINAE; ESCHERICHIA COLI; MUS; ORYCTOLAGUS CUNICULUS;

ANIMALS; BACTERIAL TOXINS; BACTERIAL VACCINES; CERCOPITHECUS AETHIOPS; CLOSTRIDIUM DIFFICILE; CRICETINAE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; LIPOPROTEINS; MICE; MICE, INBRED BALB C; RABBITS; RECOMBINANT FUSION PROTEINS; VERO CELLS;

EID: 84938792696     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/s12929-015-0171-x     Document Type: Article

References (35)

1. Knoop FC, Owens M, Crocker IC. Clostridium difficile: clinical disease and diagnosis. Clin Microbiol Rev. 1993;6(3):251-65.
2. Lyerly DM, Krivan HC, Wilkins TD. Clostridium difficile: its disease and toxins. Clin Microbiol Rev. 1988;1(1):1-18.
3. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med. 2008;359(18):1932-40.
4. McDonald LC, Killgore GE, Thompson A, Owens RC, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353(23):2433-41.
5. He M, Miyajima F, Roberts P, Ellison L, Pickard DJ, Martin MJ, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2013;45(1):109-13.
6. Sun X, Savidge T, Feng H. The enterotoxicity of Clostridium difficile toxins. Toxins. 2010;2(7):1848-80.
7. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature. 2010;467(7316):711-3.
8. Davies AH, Roberts AK, Shone CC, Acharya KR. Super toxins from a super bug: structure and function of Clostridium difficile toxins. Biochem J. 2011;436(3):517-26.
9. Fernie DS, Thomson RO, Batty I, Walker PD. Active and passive immunization to protect against antibiotic associated caecitis in hamsters. Dev Biol Stand. 1983;53:325-32.
10. Kim PH, Iaconis JP, Rolfe RD. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun. 1987;55(12):2984-92.
11. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357(9251):189-93.
12. Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection. Vaccine. 2010;28(4):965-9.
13. Davies NL, Compson JE, Mackenzie B, O'Dowd VL, Oxbrow AK, Heads JT, et al. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clin Vaccine Immunol. 2013;20(3):377-90.
14. Marozsan AJ, Ma D, Nagashima KA, Kennedy BJ, Kang YK, Arrigale RR, et al. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis. 2012;206(5):706-13.
15. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamster. Infect Immun. 2006;74(11):6339-47.
16. Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun. 1998;66(5):2018-25.
17. Wang H, Sun X, Zhang Y, Li S, Chen K, Shi L, et al. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun. 2012;80(8):2678-88.
18. Anosova NG, Brown AM, Li L, Liu N, Cole LE, Zhang J, et al. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters. J Med Microbiol. 2013;62(Pt9):1394-404.
19. Torres JF, Lyerly DM, Hill JE, Monath TP. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun. 1995;63(12):4619-27.
20. Sauerborn M, Leukel P, von Eichel-Streiber C. The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality. FEMS Microbiol Lett. 1997;155(1):45-54.
21. Seregin SS, Aldhamen YA, Rastall DP, Godbehere S, Amalfitano A. Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine. 2012;30(8):1492-501.
22. Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine. 2012;30(28):4249-58.
23. Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean TI, Calderwood SB. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun. 1997;65(7):2941-9.
24. Ward SJ, Douce G, Figueiredo D, Dougan G, Wren BW. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun. 1999;67(5):2145-52.
25. Gardiner DF, Rosenberg T, Zaharatos J, Franco D, Ho DD. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine. 2009;27(27):3598-604.
26. Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J, Fairweather NF, et al. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun. 2011;79(6):2295-302.
27. Ho JG, Greco A, Rupnik M, Ng KK. Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. Proc Natl Acad Sci U S A. 2005;102(51):18373-8.
28. Dove CH, Wang SZ, Price SB, Phelps CJ, Lyerly DM, Wilkins TD, et al. Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun. 1990;58(2):480-8.
29. Krivan HC, Clark GF, Smith DF, Wilkins TD. Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun. 1986;53(3):573-81.
30. Huang JH, Shen ZQ, Lien SP, Hsiao KN, Leng CH, Chen CC, et al. Biochemical characterizations of the receptor binding domains of C. difficile Toxin A. PLoS ONE 2015; In press.
31. Huang JH, Wu CW, Lien SP, Hsiao KN, Leng CH, Lin YH, et al. Biochemical and immunological characterizations of the receptor binding domain of C. difficile toxin B. J Vaccines Vaccin. 2015;6(2):276.
32. Chen HW, Liu SJ, Liu HH, Kwok Y, Lin CL, Lin LH, et al. A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine. 2009;27(9):1400-9.
33. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223(1):77-92.
34. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, et al. Toxin B is essential for virulence of Clostridium difficile. Nature. 2009;458(7242):1176-9.
35. Hussack G, Arbabi-Ghahroudi M, van Faassen H, Songer JG, Ng KK, Mackenzie R, et al. Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain. J Biol Chem. 2011;286(11):8961-76.